Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non-small cell lung cancer patients treated with radiotherapy

Moonkyoo Kong | Yu Jin Lim

Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea

Correspondence
Moonkyoo Kong, Division of Lung & Head and Neck Oncology, Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-gil, Dongdaemoon-gu, Seoul, 02447, Republic of Korea.
Email: kongmoonkyoo@khu.ac.kr

Funding information
This research was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea, Grant/Award Numbers: HI18C1944, HI20C1405

Abstract
Background: The level of hemoglobin A1c (HbA1c) might be associated with the severity of tumor hypoxia in patients with cancer. Here, we evaluated the association between the level of HbA1c and survival outcome in stage III non-small cell lung cancer patients treated with radical radiotherapy.

Methods: We retrospectively analysed the clinical data of 104 patients with lung cancer treated with radiotherapy. The HbA1c levels of all patients were checked 1 week before the start of radiotherapy. Survival outcomes were analysed according to the HbA1c level.

Results: The 1-, 2-, and 3-year locoregional recurrence-free survival rates were 88.3%, 68.8%, and 63.0%, respectively, in the patient group with HbA1c levels \( \leq 6\% \) and 75.5%, 54.4%, and 41.8%, respectively, in the patient group with HbA1c levels >6\% \( (p = 0.015) \). The HbA1c level remained a significant prognostic factor for locoregional recurrence-free survival on multivariable analysis (hazard ratio = 2.014, 95% confidence interval = 1.088–3.726, \( p = 0.026 \)).

Conclusions: Pretreatment HbA1c level is a significant prognostic factor for locoregional recurrence-free survival in patients with stage III non-small cell lung cancer treated with radical radiotherapy. Routine monitoring of pretreatment HbA1c levels and aggressive glycemic control may be considered to prevent the development of locoregional recurrence in these patients.

KEYWORDS
hemoglobin A1c, locoregional recurrence, lung cancer, radiotherapy

INTRODUCTION

In 1909, Schwarz reported that the radiation response of tumors was reduced when blood flow to the tumor decreased.\(^1\) Now, it is well known that oxygen is a potent chemical modifier of radiosensitivity and that hypoxic tumors show poor local control after radiotherapy.\(^2–4\)

In diabetes mellitus, a chronic hyperglycemic state causes inflammation, oxidative stress, and subsequent endothelial dysfunction, and microvascular/macrovacular occlusion. In addition, chronic hyperglycemia causes alterations in blood viscosity and hemodynamic balance, which contribute to microvascular occlusion and tissue ischemia.\(^5–8\) These changes caused by chronic hyperglycemia can aggravate tumor hypoxia.

Since the vasculature of tumors is immature and unstable,\(^9–11\) vascular occlusion and subsequent tissue hypoxia which caused by a chronic hyperglycemic state can be more serious in tumors.

Hemoglobin A1c (HbA1c) reflects the mean plasma glucose level for the previous approximately 3 months and has low intraindividual variability.\(^12,13\) Several studies have reported that elevated HbA1c levels are an independent risk factor for vascular complication.\(^14–16\) Therefore, we can assume that HbA1c levels may be associated with the severity of tumor hypoxia in patients with cancer. Given that hypoxic tumors are resistant to radiotherapy, we can also assume that HbA1c levels may be associated with the development of local recurrence in cancer patients who treated with radiotherapy.
In this study, we evaluated the association between HbA1c levels and survival outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with radical radiotherapy.

**METHODS**

The inclusion criteria were patients with histologically proven stage III non-small cell lung cancer, who received radical radiotherapy with or without chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status \( \leq 2 \), no prior thoracic irradiation, no previous or concurrent illness that would compromise the completion of treatment, and available follow-up data. Patients who received postoperative or palliative radiotherapy were excluded from the study. Patients without evaluable pretreatment HbA1c levels were also excluded. From January 2011 to May 2019, 448 patients with pathologically-confirmed stage III NSCLC received radiotherapy at our institution. Of these patients, we excluded 79 who received postoperative radiotherapy, 72 who received palliative radiotherapy, 62 who had prior thoracic irradiation history, 42 who did not have available follow-up data, and 37 who had poor general condition (ECOG performance status \( \geq 3 \)). Fifty-two patients without evaluable pretreatment HbA1c levels were also excluded. Finally, 104 patients met the inclusion criteria and were included in the study. The hospital records, including results of imaging and laboratory studies of all study participants, were retrospectively reviewed. The Institutional Review Board of our institution approved this retrospective study (KHUH-2021-04-069) and waived the need for written informed consent because it was a retrospective observational study. The study was conducted in compliance with the principles of the Helsinki Declaration and was registered in the CRIS Registration System (KCT0006199).

The detailed methods of initial diagnosis and pre-treatment evaluation have been described in our previous studies. Briefly, pretreatment evaluation consisted of complete history and physical examination, basic laboratory studies, pulmonary function test, electrocardiogram, trans-thoracic echocardiogram, chest radiography, chest computed tomography (CT) scan, brain magnetic resonance imaging, bone scan, and positron emission tomography (PET). The HbA1c levels of all patients were checked 1 week before the start of radiotherapy.

All patients received CT-planned radiotherapy. The detailed radiotherapy methods have been described in our previous study. Briefly, the primary tumor and grossly involved lymph nodes were the targets of radiotherapy, and elective nodal irradiation was not performed. The implementation and regimen of chemotherapy were individualized based on each patient's performance status and compliance. Follow-up visits were scheduled 2 weeks after completion of radiotherapy and every 2–3 months thereafter. At the follow-up visit, basic laboratory studies, chest radiographs, and chest CT scans were performed. PET was also performed as required.

The primary endpoint of this study was locoregional recurrence-free survival. The secondary endpoints were

| TABLE 1 Patient and tumor characteristics |
|------------------------------------------|
| **Characteristics** | **N (%)** |
| Age (years) | Median (range) 72 (45–85) |
| Gender | Male/female 85 (81.7)/19 (18.3) |
| Diabetes mellitus | Yes/no 25 (24.1)/79 (75.9) |
| Smoking status | Current/former/never 56 (53.8)/28 (26.9)/20 (19.3) |
| ECOG performance status | 0/1/2 13 (12.5)/67 (64.4)/24 (23.1) |
| Histology | SqCC/adeno/adenoSqCC 69 (67.3)/34 (31.7)/1 (1) |
| AJCC stage | IIA/IIIB 63 (60.6)/41 (39.4) |
| Location | Right/left 46 (44.2)/58 (55.8) |
| Upper & middle/lower | 67 (64.4)/37 (35.6) |
| RT technique | IMRT/3D-CRT 34 (32.7)/70 (67.3) |
| Total dose (BED, Gy10) | Median (range) 76.2 (70–84.4) |
| Daily dose (Gy) | Median (range) 2 (1.8–2.5) |
| RT interruption | Yes/no 22 (21.2)/82 (78.8) |
| RT duration (weeks) | Median (range) 7 (5–9) |
| Chemotherapy | Yes/no 59 (56.7)/45 (43.3) |
| Types of chemotherapy | Concurrent/sequential 45 (76.2)/14 (23.8) |
| Hemoglobin A1c (%) | Median (range) 6 (4.4–10.6) |
| Fasting glucose (mg/dl) | Median (range) 121 (81–301) |
| Hemoglobin (g/dl) | Median (range) 11.8 (7.6–15.5) |

**Abbreviations:** Adeno, adenocarcinoma; AdenoSqCC, adenosquamous cell carcinoma; AJCC, American Joint Committee on Cancer; BED, biologically equivalent dose; ECOG, Eastern Cooperative Oncology Group; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; SqCC, squamous cell carcinoma; 3D-CRT, three-dimensional conformal radiotherapy.
overall survival and distant metastasis-free survival. The locoregional recurrence and distant metastasis were defined in our previous study.17 Actuarial survival rates were estimated using the Kaplan–Meier method, and comparisons between groups were performed using log-rank tests. Survival times were calculated from the date of lung cancer diagnosis to the date of the event or the final follow-up visit. Variables found to have a $p$-value $<0.50$ on univariable analysis were further analysed by multivariable analysis using Cox's proportional hazard regression test with the enter method. All tests were two-sided, and the threshold for statistical significance was set at $p < 0.05$. All analyses were performed using SPSS version 21.0 (IBM Corporation).

RESULTS

Patient and tumor characteristics are summarized in Table 1. Forty-five patients received concurrent chemotherapy with a regimen of weekly paclitaxel plus carboplatin. Among them, three and six patients received additional induction chemotherapy and consolidation chemotherapy, respectively, in conjunction with concurrent chemotherapy. Fourteen patients received induction chemotherapy alone with a regimen of cisplatin plus etoposide. The remaining 45 patients underwent radical radiotherapy alone. Although 22 patients experienced temporary radiotherapy interruption due to treatment-related toxicities, all patients completed the planned treatment. The median follow-up duration of all patients was 21.0 months (range, 2.1–88.2).

The survival outcomes of all patients are summarized in Table 2. During the follow-up period, 54 patients remained alive. Almost all the deceased patients died due to cancer progression and cancer-related complications. However, two died of coronary heart disease, three died of chronic renal failure, two died of cerebral hemorrhage, and two died of liver cirrhosis. In addition, three patients died of acute renal failure, sepsis, and asphyxia caused by food aspiration, respectively. The 1-, 2-, and 3-year overall survival rates of all patients were 81.6%, 54.9%, and 48.8%, respectively.

During the follow-up period, 49 patients experienced locoregional recurrences and 41 patients experienced distant metastases. Among these patients, 27 experienced both locoregional recurrences and distant metastases. Among the 22 patients who only experienced locoregional recurrences without distant metastasis, eight received salvage concurrent chemoradiotherapy, five received salvage surgical resection, two received salvage radiotherapy alone, while seven refused salvage treatment. The 1-, 2-, and 3-year locoregional recurrence-free survival rates of all patients were 63.1%, 52.8%, and 45.6%, respectively. Almost all 41 patients who experienced distant metastases received palliative chemotherapy, except for six patients who refused

| Endpoint                           | Survival rate (%) | Median survival time (months) |
|-----------------------------------|-------------------|------------------------------|
| Overall survival                  | 81.6              | 54.9                         | 48.8 | 21.0 |
| Locoregional recurrence-free survival | 63.1              | 52.8                         | 45.6 | 12.1 |
| Distant metastasis-free survival  | 70.0              | 55.2                         | 51.5 | 13.1 |

**TABLE 2** Survival outcomes of the whole cohort

| Characteristics         | HbA1c (%) | ≤6 (n = 55) | >6 (n = 49) | p-value |
|-------------------------|----------|------------|-------------|---------|
| Age (years)             |          | Median (range) | 71 (45–85) | 73 (52–82) | 0.542 |
| Gender                  |          | Male/female | 47/8        | 38/11   | 0.298 |
| Diabetes mellitus       |          | Yes/no     | 4/51        | 21/28   | <0.001 |
| Smoking status          |          | Current/former/never | 26/18/11 | 30/10/9 | 0.296 |
| ECOG performance status |          | 0/1/2      | 7/30/18     | 6/37/6  | 0.069 |
| Histology               |          | SqCC/adeno/adenoSqCC | 42/12/1 | 28/21   | 0.043 |
| AJCC stage              |          | IIIA/IIIB  | 36/19       | 27/22   | 0.281 |
| Location                |          | Right/left | 24/31       | 22/27   | 0.863 |
| Upper and middle/lower  |          | 39/16      | 28/21       | 0.285   |
| RT technique            |          | IMRT/3D-CRT | 22/45       | 12/25   | 0.571 |
| Total dose (BED, Gy10)  |          | Median (range) | 76.2 (70–84) | 76.2 (70–84.4) | 0.873 |
| Daily dose (Gy)         |          | Median (range) | 2 (1.8–2.5) | 2 (1.8–2.4) | 0.699 |
| RT interruption         |          | Yes/no     | 12/43       | 10/39   | 0.794 |
| RT duration (weeks)     |          | Median (range) | 7 (5–9)     | 7 (5–9) | 0.913 |
| Chemotherapy            |          | Yes/no     | 30/25       | 29/20   | 0.375 |
| Types of chemotherapy   |          | Concurrent/sequential | 23/7   | 22/7   | 0.214 |
| Fasting glucose (mg/dl) |          | Median (range) | 115 (81–236) | 137 (81–301) | 0.007 |
| Hemoglobin (g/dl)       |          | Median (range) | 11.7 (7.8–15.5) | 12.1 (7.6–14.8) | 0.897 |

**TABLE 3** Patient and tumor characteristics of low and high HbA1c groups

Abbreviations: Adeno, adenocarcinoma; AdenoSqCC, adenosquamous cell carcinoma; AJCC, American Joint Committee on Cancer; BED, biologically equivalent dose; ECOG, Eastern Cooperative Oncology Group; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy.

...
### DISCUSSION

This retrospective study evaluated the association between pretreatment HbA1c levels and survival outcomes in 104 patients with stage III NSCLC and found that the HbA1c level, which was checked 1 week before the start of radiotherapy, is a significant prognostic factor for locoregional recurrence-free survival in patients with stage III NSCLC who were treated with radical radiotherapy. The patient group with HbA1c >6% had a higher risk of developing locoregional recurrence than the group with HbA1c ≤6%, with a relative risk was 2.014. To the best of our knowledge, this is the first study to report the impact of HbA1c on the development of locoregional recurrence in patients with lung cancer treated with radiotherapy. Although this is a retrospective study with inherent biases, HbA1c can be combined with existing prognostic factors to allow personalized treatment for patients with lung cancer. We hope that further studies are conducted to confirm our results and the efficacy of personalized treatment combining HbA1c and existing prognostic factors in patients with lung cancer treated with radiotherapy.

Tissue oxygenation is critically dependent on capillary blood flow, which is determined by the arteriovenous pressure difference and vascular architecture. In tumors, mechanical stress generated by proliferating tumor cells, imbalance between pro- and antiangiogenic molecules, and incomplete vascular differentiation causes tortuous vessels, sluggish blood flow, blood shunting, temporary occlusion, and hyperpermeability of vessels. As a result, overall perfusion rates in tumors are lower than those in normal tissues, and this contributes to both acute and chronic hypoxia in tumors. The mechanism by which diabetes contributes to vascular complications is not clear, but it has been reported that chronic hyperglycemia is an important and initiating insult. A long-standing hyperglycemic state triggers an increase in oxidative stress and inflammatory response, alteration in cellular redox potential, accumulation of advanced glycosylation end products in the subendothelial space, and the development of endothelial dysfunction and hypercoagulability. All these changes can cause large and small vessel obstructions. In summary, unstable and tortuous vessels of the tumor can be easily obstructed, therefore tumor hypoxia becomes worse in a chronic hyperglycemic state. These may be the reasons why patients with higher pretreatment HbA1c levels showed worse...
locoregional recurrence-free survival than patients with lower HbA1c levels in our study. However, the proposed reasons are still a matter of speculation, and in-vivo and in-vitro experimental studies are required to confirm whether tumor hypoxia is aggravated in a chronic hyperglycemic state.

Some studies have reported that tumor hypoxia itself is correlated with aggressiveness. Hockel et al. reported that the oncological outcome of patients with cervical cancer treated with surgical resection only is also correlated with tumor hypoxia.24 In addition, Graeber et al. reported that hypoxia provides a growth advantage for cells with mutated p53 and can select for more aggressive tumors.25 Therefore, caution is required when interpreting our results. We previously reported that poor locoregional recurrence-free survival in patients with higher HbA1c levels was caused by decrease in the radiation response of hypoxic tumors which was aggravated in the chronic hyperglycemic state. However, the aggressiveness of tumor hypoxia itself could be the reason for the poor survival outcome. At present, we do not know the exact mechanism underlying our results. However, because the HbA1c level was significantly associated with only locoregional recurrence-free survival and not with distant metastasis-free survival (Table 4), we believe that the radiation resistance of hypoxic tumors, which aggravated in long-standing hyperglycemic state, was a more powerful reason for the poor survival outcome of patients with higher HbA1c levels in our study. Regardless of the reasons, the fact that the HbA1c level is a significant prognostic factor for patients with lung cancer remains unchanged.

Diabetes mellitus and diabetes-related serological factors such as HbA1c and fasting glucose are highly correlated

### Table 5: Prognostic factors for locoregional recurrence-free survival

| Variables                             | Univariable 2-year survival rate (%) | 2-year survival rate (%) | p-value | Hazard ratio | 95% confidence interval | p-value |
|---------------------------------------|--------------------------------------|--------------------------|---------|--------------|-------------------------|---------|
| **Age (years)**                       |                                      |                          |         |              |                         |         |
| <72 vs. ≥72                           | 36.7 vs. 68                          | 0.032                    | 0.514   | 0.263–1.005  | 0.052                   |         |
| **Gender**                            |                                      |                          |         |              |                         |         |
| Male vs. female                       | 49.8 vs. 67.3                        | 0.258                    | 0.464   | 0.155–1.388  | 0.169                   |         |
| **Diabetes mellitus**                 |                                      |                          |         |              |                         |         |
| Yes vs. no                            | 54.4 vs. 51.8                        | 0.875                    |         |              |                         |         |
| **Smoking status**                    |                                      |                          |         |              |                         |         |
| Current vs. former or never           | 49.2 vs. 57.9                        | 0.724                    |         |              |                         |         |
| **ECOG performance status**           |                                      |                          |         |              |                         |         |
| 0–1 vs. 2                             | 51.4 vs. 65.5                        | 0.785                    |         |              |                         |         |
| **Histology**                         |                                      |                          |         |              |                         |         |
| SqCC vs. adeno                        | 53.8 vs. 49.3                        | 0.349                    | 1.652   | 0.806–3.385  | 0.170                   |         |
| **AJCC stage**                        |                                      |                          |         |              |                         |         |
| IIIA/IIIB                             | 54 vs. 50.5                          | 0.297                    | 0.986   | 0.501–1.939  | 0.967                   |         |
| **RT technique**                      |                                      |                          |         |              |                         |         |
| IMRT/3D-CRT                           | 51.6 vs. 53.6                        | 0.880                    |         |              |                         |         |
| Total dose (BED, Gy10)                |                                      |                          |         |              |                         |         |
| ≤76 vs. >76                           | 52.1 vs. 52.6                        | 0.738                    |         |              |                         |         |
| Daily dose (Gy)                       |                                      |                          |         |              |                         |         |
| ≤2 vs. >2                             | 56.9 vs. 48.9                        | 0.660                    |         |              |                         |         |
| RT duration (weeks)                   |                                      |                          |         |              |                         |         |
| <7 vs. ≥7                             | 48.4 vs. 57.2                        | 0.418                    | 0.845   | 0.459–1.554  | 0.588                   |         |
| **Chemotherapy**                      |                                      |                          |         |              |                         |         |
| Yes vs. no                            | 47.6 vs. 58.3                        | 0.120                    | 0.883   | 0.420–1.851  | 0.740                   |         |
| **Hemoglobin A1c (%)**                |                                      |                          |         |              |                         |         |
| ≤6 vs. >6                             | 63 vs. 41.8                          | 0.015                    | 2.014   | 1.088–3.726  | 0.026                   |         |
| **Fasting glucose (mg/dl)**           |                                      |                          |         |              |                         |         |
| ≤120 vs. >120                         | 57.1 vs. 48.6                        | 0.150                    | 1.217   | 0.639–2.316  | 0.550                   |         |
| **Hemoglobin (g/dl)**                 |                                      |                          |         |              |                         |         |
| ≤11.8 vs. ≥11.8                       | 58.4 vs. 47                          | 0.585                    |         |              |                         |         |

Abbreviations: Adeno, adenocarcinoma; AJCC, American Joint Committee on Cancer; BED, biologically equivalent dose; ECOG, Eastern Cooperative Oncology Group; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; SqCC, squamous cell carcinoma; 3D-CRT, three-dimensional conformal radiotherapy.

*aFirst group was reference category for calculation of hazard ratio and 95% confidence interval.*
with one another. In our previous study, we evaluated the effects of preexisting diabetes and diabetes-related serological factors on the development of radiation pneumonitis.\textsuperscript{26} We retrospectively analysed the clinical data of 123 lung cancer patients treated with radiotherapy and found that pre-existing diabetes, HbA1c, and fasting glucose level were significant predictive factor for the development of grade $\geq$3 radiation pneumonitis. However, only HbA1c was significantly associated with locoregional recurrence-free survival in current study. If properly treated, diabetic patients can maintain good glycemic control. Because of requirement for an overnight fast, checking of fasting glucose level is inconvenient and fasting glucose has high variability.\textsuperscript{27} On the other hand, HbA1c reflect the long-term mean plasma glucose level and has stability after collection, low variability, and no requirement for an overnight fast. Therefore, the American Diabetes Association have advocated measurement of HbA1c as the preferred approach to the diagnosis and management of hyperglycemia.\textsuperscript{28} Moreover, although preexisting diabetes, fasting glucose, and HbA1c levels were significantly associated with development of radiation pneumonitis, HbA1c was most powerful factor among them in our previous study.\textsuperscript{29} Therefore, we believe that HbA1c level may reflect chronic tumor hypoxia better than pre-existing diabetes and fasting glucose level. Researchers who plan to conduct additional studies should keep this in mind.

There were some limitations to this study. First, this study was retrospective, so may have inherent biases. For example, we excluded patients without evaluable pretreatment HbA1c levels, which may introduce an unintended selection bias. In addition, we could not include a medication history of diabetes in our analysis because of incomplete medical records. These biases may make it difficult to interpret the results obtained. Second, the sample size was small, so minor differences might not have been detected during statistical analysis. Third, the treatment characteristics were heterogeneous. Radiotherapy fractionation schedules and chemotherapy regimens were decided by the attending physicians rather than using a predetermined protocol. Finally, the duration of the follow-up period was not long.

Despite these limitations, we firstly found an association between HbA1c levels and locoregional recurrence in patients with lung cancer treated with radiotherapy. Although large-scale randomized prospective studies should be conducted to confirm our results, HbA1c could serve as a helpful prognostic factor, and routine evaluation of pretreatment HbA1c levels should be considered in patients with stage III NSCLC treated with radical radiotherapy. And, additional studies are required to determine whether aggressive glycemic control can increase radiotherapy response and locoregional recurrence-free survival in patients with lung cancer. Recent two prospective randomized clinical trials (the NRG-LU001 and the OCOG-ALMERA trials) reported that the addition of metformin to concurrent chemoradiotherapy did not improve progression-free survival in nondiabetic patients with stage III NSCLC,\textsuperscript{29,30} although several preclinical and retrospective studies have reported antineoplastic effect of metformin. The retrospective data may have biases, being drawn from a population with diabetes. Therefore, favorable survival outcomes of retrospective studies could be originated from glycemic control effect of metformin rather than direct antineoplastic effect. We plan to conduct additional studies to identify whether the differences between pre- (1 week before the start) and post-treatment (3 months after the completion) HbA1c level are associated with radiotherapy response in patients with lung cancer. In a similar way, the differences between pre- (1 week before the start) and post-treatment (1 month after the completion) glycoalbumin level can be evaluated to identify its relevance to oncologic outcomes in lung cancer patients treated with radical radiotherapy. Through these studies, we hope to find the answer to question whether better glycemic control increase radiotherapy response or not. In addition, it will be necessary to conduct further studies evaluating the efficacy of HbA1c levels in several cancers other than lung cancer.

In conclusion, the pretreatment HbA1c level is a significant prognostic factor for locoregional recurrence-free survival in patients with stage III NSCLC treated with radical radiotherapy. Routine monitoring of pretreatment HbA1c levels and aggressive glycemic control may be considered to prevent the occurrence of locoregional recurrence in these patients.

ACKNOWLEDGMENTS
The authors would like to thank Jeenyung Kong for writing assistance and Editage (www.editage.co.kr) for English language editing.

CONFLICT OF INTEREST
This research was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI18C1944, HI20C1405).

ORCID
Moonkyoo Kong (https://orcid.org/0000-0003-3703-0417)
Yu Jin Lim (https://orcid.org/0000-0003-2243-8989)

REFERENCES
1. Schwartz G. Ueber Desensibilisierung gegen rontgen und radiumstrahlen. Muench Med Wochenschr. 1909;24:1–2.
2. Deschner EE, Gray LH. Influence of oxygen tension on x-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo. Radiat Res. 1959;11:115–46.
3. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–43.
4. Hockel M, Schlegel K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3–9.
5. Dominguetti CP, Dusse LM, Carvalho M, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016;30:738–45.
6. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development
of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171–82.
7. Margetic S. Inflammation and haemostasis. Biochem Med (Zagreb). 2012;22:49–62.
8. Dubin R, Cushman M, Folsom AR, Fried LF, Palmas W, Peralta CA, et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol. 2011;12:3.
9. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685–93.
10. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature. 2004;427:695.
11. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988;48:692–8.
12. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545–51.
13. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diab Res Pract. 2009;32:1327–34.
14. Albashir AAD, Elawad O, Khougali HS. The use of glycosylated hemoglobin (HbA1c) as a predictor of the severity of acute coronary syndrome among diabetic patients. Ir J Med Sci. 2021;190:609–14.
15. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2006;29:877–82.
16. Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A(1c) level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006;97:968–9.
17. Kong M, Sung JY, Lee SH. Reactive oxygen species modulator 1 as an adverse prognostic marker in stage III non-small cell lung cancer treated with radiotherapy: a retrospective pilot study. Onco Targets Ther. 2019;12:8263–73.
18. Kong M, Sung JY, Lee SH. Reactive oxygen species modulator 1 is associated with poor survival in patients with non-small cell lung cancer after stereotactic fractionated radiotherapy: a retrospective pilot study. Onco Targets Ther. 2020;13:8173–80.
19. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol. 1997;15:778–83.
20. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–65.
21. Poston L, Taylor PD. Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci (Lond). 1995;88:245–55.
22. Wautier JL, Guillaumeau PJ. Diabetes, advanced glycation end-products and vascular disease. Vasc Med. 1998;3:131–7.
23. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87:432–8.
24. Hockel M, Schlegner K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999;59:4525–8.
25. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91.
26. Kong M, Lim YJ, Kim Y, Chung MJ, Min S, Shin DO. Diabetes mellitus is a predictive factor for radiation pneumonitis after thoracic radiotherapy in patients with lung cancer. Cancer Manag Res. 2019;11:7103–10.
27. Kim JA, Lee JS, Chung HS, Roh E, Lee YB, Hong SH, et al. Impact of visit-to-visit fasting plasma glucose variability on the development of type 2 diabetes: a nationwide population-based cohort study. Diabetes Care. 2018;41:2610–6.
28. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11–61.
29. Skinner H, Hu C, Tsakiridis T, Santana-Davila R, Lu B, Erasmus JJ, et al. Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer: the NRG-LU001 phase 2 randomized clinical trial. JAMA Oncol. 2021;7:1324.
30. Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmed N, Abdulkarim B, et al. Metformin in combination with chemoradiotherapy in locally advanced non-small cell lung cancer: the OCGO-ALMERA randomized clinical trial. JAMA Oncol. 2021;7:1333.